منابع مشابه
Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15
Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...
متن کاملGM-CSF Signalling Boosts Dramatically IL-1Production
GM-CSF is mostly known for its capacity to promote bone marrow progenitor differentiation, to mobilize and mature myeloid cells as well as to enhance host immune responses. However the molecular actions of GM-CSF are still poorly characterized. Here we describe a new surprising facet of this "old" growth factor as a key regulator involved in IL-1β secretion. We found that IL-1β release, a pivot...
متن کاملwhole tumor cell vaccine adjuvants: comparing il-12 to il-2 and il-15
cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. cancer vaccines induce pe...
متن کاملWhole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.
Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...
متن کاملAbiraterone Boosts Prostate Cancer Survival
Final results of a phase III trial confirm that treatment with abiraterone prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel therapy. Over a median 20 month follow-up, median OS was 15.8 months for abiraterone (Zytiga®) plus prednisone compared with 11.2 months for placebo plus the steroid (P<0.0001), Karim Fizazi, MD, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 1999
ISSN: 1087-0156,1546-1696
DOI: 10.1038/7846